PET en el diagnóstico de la patología de tiroides

  1. Luis Gonzaga DÍAZ-GONZÁLEZ 1
  2. Paloma GARCÍA-TALAVERA 1
  3. Felipe GÓMEZ-CAMINERO 1
  4. Cristina RIOLA-PARADA 1
  5. Juan Gabriel VILLANUEVA-CURTO 1
  6. Pilar TAMAYO-ALONSO 1
  1. 1 Hospital Universitario de Salalamanca
Revista:
Revista ORL

ISSN: 2444-7986,  2444-7986

Año de publicación: 2020

Volumen: 11

Volumen: 3

Páginas: 297-304

Tipo: Artículo

DOI: 10.14201/ORL.21520 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: Revista ORL

Resumen

Introducción y objetivo: La PET/TC es una técnica cuyas indicaciones en Oncología se encuentran en expansión y el cáncer de tiroides es una de ellas. Método: Revisión narrativa. Comentarios: En el presente artículo se revisan las indicaciones establecidas hasta la fecha, así como aquellos campos en los que son necesarias investigaciones adicionales que permitan establecer la utilidad de esta técnica en los distintos tipos de patología maligna tiroidea.

Referencias bibliográficas

  • Basu S, Kumar R, Ranade R. Assessment of treatment response using PET. PET Clin. 2015; 10(1):9-26.
  • Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, et al. Is (18)F-fluorodeoxyglucose- PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid. 2012; 22(2):165-72.
  • Feine U, Lietzenmayer R, Hanke JP, Wohrle H, Muller-Schauenburg W. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. Nuklearmedizin. 1995; 34(4):127-34.
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1):1-133.
  • Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, et al. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J. 2010; 57(12):1045-54.
  • Kloos RT. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab. 2008; 93(5):1519-25.
  • Kushchayev SV, Kushchayeva YS, Tella SH, Glushko T, Pacak K, Teytelboym OM. Medullary Thyroid Carcinoma: An Update on Imaging. J Thyroid Res. 2019; 2019:1893047.
  • Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014; 202(6):1316-29.
  • Muros de Fuentes MA, Mitjavila Casanovas M, Estorch Cabrera M, Lecumberri Santamaria B, Navarro Gonzalez E. Usefulness of 18F-FDG PET/CT in thyroid carcinoma. Rev Esp Med Nucl Imagen Mol. 2016; 35(3):186-92.
  • Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, et al. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid. 2015; 25(4):437-44.
  • Riola-Parada C, Garcia-Canamaque L, Perez- Duenas V, Garcerant-Tafur M, Carreras-Delgado JL. Simultaneous PET/MRI vs PET/CT in oncology. A systematic review. Rev Esp Med Nucl Imagen Mol. 2016; 35(5):306-12.
  • Skoura E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013; 11(4):e8156.
  • Treglia G, Annunziata S, Muoio B, Salvatori M, Ceriani L, Giovanella L. The role of fluorine- 18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. Int J Endocrinol. 2013; 2013:856189.
  • Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine- 18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012; 19(10):1290-9.
  • Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017; 16(4):362-72.
Fuente de los datos: Dialnet